Titan makes further cuts
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticalsis to make further staff cuts, this time to top management positions to reduce its expenses and operations. Marc Rubin, president and CEO, and Sunil Bhonsle, chief operating officer, are to leave the company. However, both will continue to assist the company in the development of its most clinically advanced product, Probupine (buprenorphine in an ethylene-vinyl acetate rod), for the treatment of opioid addiction. The company reduced its workforce by 40% earlier this month, and at the time warned that it would make further cuts in the following weeks (ScripOnline, December 2nd, 2008). Robert Farrell, currently chief financial officer, will now assume the role of president. Titan has filed with the SEC to delist voluntarily from the American Stock Exchange and to suspend its reporting obligations.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.